

Special Issue

Extracellular Matrix and Vesicles as Immunomodulatory Therapeutics

Message from the Guest Editors

In this Special Issue of *Pharmaceutics*, titled “Extracellular Matrix and Vesicles as Immunomodulatory Therapeutics”, we delve into the implications of utilizing extracellular matrix (ECM)-based biomaterials and extracellular vesicles (EVs) as immune response-modulating agents. ECM and EVs play essential roles in the response and coordination of the immune system in health and disease, which qualifies them as powerful tools (both on their own or combined) for immunomodulatory agents. The importance of this field is further underscored by their potential to develop targeted immunotherapies and chronic inflammation treatments with enhanced efficacy and reduced side effects. Hence, the purpose of this Special Issue is to showcase the latest research on the pharmaceutical applications of ECM and extracellular vesicle-based therapeutics alone or combined, including their design, optimization, and therapeutic immunomodulatory efficacy. This collection aims to provide a comprehensive overview of how these innovative approaches can be harnessed to advance drug delivery and immunomodulation to clinical translation.

Guest Editors

Dr. Amiq Gazdhar

Dr. Héctor Capella-Monsonís

Dr. William D’Angelo

Dr. Ana Isabel Flores

Deadline for manuscript submissions

31 March 2025



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



mdpi.com/si/218951

Pharmaceutics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).